We are invited to be not merely passive onlookers of this conversation, but active participants in that dialogue that takes place in this book over the course of a single evening.
Proving an incrementally better product enhances value can be expensive (because it takes many patients to demonstrate a small difference in an active comparator trial), and of course, risky as well.